Understanding disease in the digital age

OccamzRazor is a digital biotech company that focuses on the discovery and development of modality agnostic treatments for complex diseases of brain aging. Founded by life scientists, OccamzRazor strives to supercharge human scientific reasoning through machine learning. Our integration of various machine learning techniques, such as natural language processing and graph representation learning allows us to process an unprecedented amount of high-quality data and combine it into a multidimensional knowledge map. OccamzRazor’s platform identifies disease targets and mechanisms better than any other solution as showcased at the 2020 NeurIPS conference.

We have more and better data than ever, yet clinical success is in decline.

The exponential increase of public knowledge does not translate into clinical trial success. The last decades were full of scientific breakthroughs. Over 100,000 human genomes were sequenced to date, new technologies such as CRISPR-CAS9 enable scientists to produce more high-quality data than ever. What stops us from converting that data into actionable insights for treatment options? The human capacity to cut through the vast data repositories and draw the right connections is limited. OccamzRazor is solving this problem.

Our digital scientist technology combines knowledge extraction and graph learning

 “Labeled training data is the new new oil.” 
Christopher Ré, Stanford

Together, with world leading experts from Stanford University, we developed a data labeling system to vastly accelerate
the generation of Natural Language Processing (NLP) classifiers for biomedical knowledge extraction.

Building on this technology, OccamzRazor developed the first end-to-end insight prediction pipeline. It allows us to automatically draw knowledge from millions of peer-reviewed publications, high-quality proprietary datasets, clinical trial findings, and our own lab experiments. The seamless integration of text-based and structured datasets in one knowledge map is the basis for our innovative approach to drug discovery.

Our dynamic knowledge map technology acts as a digital scientist and provides new insights for various diseases. The importance of automatically integrating text-based data to find new disease mechanisms and drug targets is a breakthrough finding that we proudly present at the 2020 NeurIPS conference.

Our key to success: A vast diversity of data brought together in one unified platform and cutting edge machine learning.

We start our discovery journey where purely human reasoning reaches its limits. Our algorithms can operate in hundreds of dimensions of information combining proteomics, genomics, imaging, and patient data to predict new ways to cure disease. After thorough digital evaluation and de-risking, we test these hypotheses in our own proprietary disease models. Our approach is extremely versatile and lean as it does not require us to set up a laboratory before we have a list of high potential disease targets in hand.

Together with our partners we keep pushing the boundaries of technology to give hope to millions of patients and their families and develop the first treatments to cure Parkinson’s disease and other brain-aging diseases. We have entered the pre-clinical stage of our first AI-generated therapies.

team

Leadership

OccamzRazor is an international assembly of biomedical scientists, bioinformaticians, and AI experts.

We value team spirit, humility, and constant learning. Since we come from various industrial and academic avenues, we foster a culture of constant exchange and mutual support to achieve our ambitious goals together.

Dr. Katharina Sophia Volz

Founder, Executive Chair of the Board, and VP of Partnerships

Katharina was Stanford University's first PhD in Stem Cell Biology & Regenerative Medicine, earning her degree in just two and a half years. Her experience in biomedical research covers over 16 years working in labs at 10 prestigious institutions around the world, including: Harvard, UCLA, HHMI, Ohio State, TU Graz and Stanford University. For her scientific work, Katharina has been awarded multiple fellowships and awards and was listed in Forbes 30u30 (Science) in 2017.

Advisors

OccamzRazor is proud to draw on the experience and expertise of some of the sharpest minds in both medical science and AI.
Our advisors are leaders in all aspects of our business and support us with key insight.

investors

OccamzRazor is a resident company of Johnson & Johnson Innovation – JLABS, a premier life science incubator program. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.

NEWS & UPDATES

OccamzRazor is always looking to push the boundaries of medical research and to find solutions to complex disease areas.

If you would like to keep up to date with our latest developments, please visit News & Updates and sign up below to join our mailing list.

You can find OccamzRazor on social media here:

 JOIN THE TEAM

This is a very exciting time for OccamzRazor. We are expanding rapidly and looking for people who want to share the journey.
Our internal culture is open and collaborative, we’re creating a space everyone can feel proud to contribute to.

Currently, we have a range of openings, but we are also happy to welcome speculative applications.

Current vacancies

Machine Learning Team Lead

 get in touch

As a forward looking company, we know that to retain our competitive edge we will form new partnerships and gain new investment in the future.

If you would like to make a preliminary enquiry or get in touch with our team please use the link below.